Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide versus lanreotide for volume reduction in polycystic liver disease
NL-OMON32446Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in Polycystic liver disease (PLD) comparing Octreotide with Lanreotide (2 arms). Primary endpoint: Change in liver volume from baseline to 24 weeks. Started Apr 2011; status: active, not recruiting.
02
Drugs
octreotidelanreotide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NL-OMON32446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32446.